341 related articles for article (PubMed ID: 32931884)
21. Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance.
Cheng B; Zhu G; Meng L; Wu G; Chen Q; Ma S
Eur J Med Chem; 2022 Jan; 228():113930. PubMed ID: 34794817
[TBL] [Abstract][Full Text] [Related]
22. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, antiproliferative activity and molecular docking of thiocolchicine urethanes.
Majcher U; Urbaniak A; Maj E; Moshari M; Delgado M; Wietrzyk J; Bartl F; Chambers TC; Tuszynski JA; Huczyński A
Bioorg Chem; 2018 Dec; 81():553-566. PubMed ID: 30248507
[TBL] [Abstract][Full Text] [Related]
24. 4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
Lin MS; Hong TM; Chou TH; Yang SC; Chung WC; Weng CW; Tsai ML; Cheng TR; Chen JJW; Lee TC; Wong CH; Chein RJ; Yang PC
Eur J Med Chem; 2019 Nov; 181():111584. PubMed ID: 31419740
[TBL] [Abstract][Full Text] [Related]
25. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
Mirzaei H; Shokrzadeh M; Modanloo M; Ziar A; Riazi GH; Emami S
Bioorg Chem; 2017 Dec; 75():86-98. PubMed ID: 28922629
[TBL] [Abstract][Full Text] [Related]
26. X-ray Crystal Structure Guided Discovery and Antitumor Efficacy of Dihydroquinoxalinone as Potent Tubulin Polymerization Inhibitors.
Arnst KE; Banerjee S; Wang Y; Chen H; Li Y; Yang L; Li W; Miller DD; Li W
ACS Chem Biol; 2019 Dec; 14(12):2810-2821. PubMed ID: 31714738
[TBL] [Abstract][Full Text] [Related]
27. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT
Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659
[TBL] [Abstract][Full Text] [Related]
28. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
29. Structural insight into SSE15206 in complex with tubulin provides a rational design for pyrazolinethioamides as tubulin polymerization inhibitors.
Ma L; Lei J; Chen H; Huang R; Su T; Feng J; Sun Q
Future Med Chem; 2022 Jun; 14(11):785-794. PubMed ID: 35506429
[No Abstract] [Full Text] [Related]
30. A novel tubulin inhibitor, 6h, suppresses tumor-associated angiogenesis and shows potent antitumor activity against non-small cell lung cancers.
Liu Z; Huang L; Zhou T; Chang X; Yang Y; Shi Y; Hao M; Li Z; Wu Y; Guan Q; Zhang W; Zuo D
J Biol Chem; 2022 Jul; 298(7):102063. PubMed ID: 35618020
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel 2-phenyl-imidazo[1,2-a]pyridine analogues targeting tubulin polymerization as antiproliferative agents.
An W; Wang W; Yu T; Zhang Y; Miao Z; Meng T; Shen J
Eur J Med Chem; 2016 Apr; 112():367-372. PubMed ID: 26927488
[TBL] [Abstract][Full Text] [Related]
32. SKLB-14b, a novel oral microtubule-destabilizing agent based on hydroxamic acid with potent anti-tumor and anti-multidrug resistance activities.
Zhang W; Yang L; Si W; Tang M; Bai P; Zhu Z; Kuang S; Liu J; Shi M; Huang J; Chen X; Li D; Wen Y; Yang Z; Xiao K; Chen L
Bioorg Chem; 2022 Nov; 128():106053. PubMed ID: 35964504
[TBL] [Abstract][Full Text] [Related]
33. A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity.
Zheng YB; Gong JH; Liu XJ; Wu SY; Li Y; Xu XD; Shang BY; Zhou JM; Zhu ZL; Si SY; Zhen YS
Sci Rep; 2016 Aug; 6():31472. PubMed ID: 27510727
[TBL] [Abstract][Full Text] [Related]
34. New ligands of the tubulin colchicine site based on X-ray structures.
Álvarez R; Medarde M; Peláez R
Curr Top Med Chem; 2014; 14(20):2231-52. PubMed ID: 25434358
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain.
Li W; Yin Y; Shuai W; Xu F; Yao H; Liu J; Cheng K; Xu J; Zhu Z; Xu S
Bioorg Chem; 2019 Mar; 83():380-390. PubMed ID: 30408650
[TBL] [Abstract][Full Text] [Related]
36. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1
Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; White SW; Miller DD; Li W; Li W
J Med Chem; 2019 Jul; 62(14):6734-6750. PubMed ID: 31251599
[TBL] [Abstract][Full Text] [Related]
37. N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin.
Wang XF; Wang SB; Ohkoshi E; Wang LT; Hamel E; Qian K; Morris-Natschke SL; Lee KH; Xie L
Eur J Med Chem; 2013 Sep; 67():196-207. PubMed ID: 23867604
[TBL] [Abstract][Full Text] [Related]
38. 1-Phenyl-dihydrobenzoindazoles as novel colchicine site inhibitors: Structural basis and antitumor efficacy.
Jiang J; Zhang H; Wang C; Zhang Q; Fang S; Zhou R; Hu J; Zhu J; Zhou Y; Luo C; Zheng C
Eur J Med Chem; 2019 Sep; 177():448-456. PubMed ID: 31174062
[TBL] [Abstract][Full Text] [Related]
39. Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity.
Arora S; Wang XI; Keenan SM; Andaya C; Zhang Q; Peng Y; Welsh WJ
Cancer Res; 2009 Mar; 69(5):1910-5. PubMed ID: 19223556
[TBL] [Abstract][Full Text] [Related]
40. Discovery of dihydrofuranoallocolchicinoids - Highly potent antimitotic agents with low acute toxicity.
Shchegravina ES; Svirshchevskaya EV; Combes S; Allegro D; Barbier P; Gigant B; Varela PF; Gavryushin AE; Kobanova DA; Shchekotikhin AE; Fedorov AY
Eur J Med Chem; 2020 Dec; 207():112724. PubMed ID: 32827941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
